Group 1 - The core viewpoint of the article highlights a significant increase in the stock price of Baiaosaitu-B (02315), which surged nearly 20% in early trading, reaching HKD 34.3 with a trading volume of HKD 22.7351 million [1] - The Shanghai Stock Exchange and Shenzhen Stock Exchange announced that Baiaosaitu-B will be added to the Hong Kong Stock Connect eligible securities list effective December 24, 2025, following the end of its price stabilization period in the Hong Kong market and after being listed for 10 trading days in A-shares [1] - Guotai Junan Securities previously noted that Baiaosaitu is a leading preclinical CRO and life technology company in China, possessing a globally advanced gene editing technology platform and abundant resources of model mice, significantly developing its antibody development business through the "Thousand Mice and Ten Thousand Antibodies" initiative, with strong growth potential in overseas markets [1]
港股异动 | 百奥赛图-B(02315)大涨近20% 今日起正式进入港股通名单